SeeThruEquity Issues Update on DelMar Pharmaceuticals Highlighting Data Presented at American Association for Cancer Research
ACCESSWIRE - Tue May 12, 8:02AM CDT
NEW YORK, NY / ACCESSWIRE / May 12, 2015 / SeeThruEquity, a leading New York City based independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued a 2Q15 update note on DelMar Pharmaceuticals, Inc. (OTCQX: DMPI), a biotechnology company focused on proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments.
DelMar Pharmaceuticals to Present Additional Data on VAL-083 as a Potential Treatment for Temozolomide-Resistant GBM at AACR Advances in Brain Cancer Research Conference
PR Newswire - Thu May 07, 7:05AM CDT
DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"
DelMar Pharmaceuticals to Present Data Supporting the Development of VAL-083 in Refractory Glioblastoma Multiforme and Non-Small Cell Lung Cancer at the American Society of Clinical Oncology (ASCO) Annual Meeting
PR Newswire - Thu Apr 30, 6:05AM CDT
DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"
DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM)
PR Newswire - Mon Apr 20, 12:00PM CDT
DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) (DelMar and the Company), a biopharmaceutical company focused on developing and commercializing proven cancer therapies in new orphan drug indications, today announced promising preclinical data at the 106th Annual Meeting of the American Association for Cancer Research (AACR) Annual Meeting on the potential for its lead product candidate VAL-083 (dianhydrogalactitol) to treat patients with temozolomide-resistant glioblastoma multiforme (GBM).
DelMar Pharmaceuticals Presents Updated Clinical Data on Phase I/II Study of VAL-083 in Refractory Glioblastoma Multiforme (GBM)
PR Newswire - Mon Apr 20, 7:00AM CDT
DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) (DelMar and the Company), a biopharmaceutical company focused on developing and commercializing proven cancer therapies in new orphan drug indications, today announced updated clinical data on the identification of maximum tolerated dose (MTD) from its Phase I/II study of its lead product candidate VAL-083 (dianhydrogalactitol) in patients with refractory glioblastoma multiforme (GBM), the most common and deadly form of human brain cancer.
DelMar Pharmaceuticals Presents Positive Preclinical Data on VAL-083 for Treatment of Non-Small Cell Lung Cancer at the American Association of Cancer Research Annual Meeting
PR Newswire - Sun Apr 19, 12:00PM CDT
DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) (DelMar and the Company), a biopharmaceutical company focused on developing and commercializing proven cancer therapies in new orphan drug indications, today announced positive preclinical data on its lead product candidate VAL-083 (dianhydrogalactitol) for treatment of platinum drug-resistant non-small cell lung cancer (NSCLC) and as a potential combination therapy option in newly diagnosed NSCLC patients.
DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma
PR Newswire - Thu Apr 16, 7:05AM CDT
DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) (DelMar and the Company), a biopharmaceutical company focused on developing and commercializing proven cancer therapies in new orphan drug indications, today announced that the Mayo Clinic Cancer Center has been added as a clinical trial site for the ongoing, multicenter Phase I/II study of VAL-083 in patients with refractory glioblastoma multiforme (GBM), the most common and deadly form of human brain cancer.
DelMar Pharmaceuticals Announces Panel Participation in Cancer Advance Boston Conference on April 14, 2015
PR Newswire - Tue Apr 07, 7:00AM CDT
DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) (DelMar and the Company), a biopharmaceutical company focused on developing and commercializing proven cancer therapies in new orphan drug indications, today announced that Jeffrey Bacha, President and CEO, will be a panelist at Cancer Advance Boston, a networking conference of the Boston Biotech Conference series, being held April 13-14, 2015, at the Joseph B. Martin Conference Center at Harvard Medical School in Boston, Massachusetts.
DelMar Pharmaceuticals Appoints Biopharmaceutical Industry Veteran, Erich Mohr, Ph.D., R.Psych., to the Board of Directors
PR Newswire - Wed Apr 01, 7:05AM CDT
DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"
SeeThruEquity Issues Update on DelMar Pharmaceuticals
ACCESSWIRE - Mon Mar 09, 8:45AM CDT
NEW YORK, NY / ACCESSWIRE / March 9, 2015 / SeeThruEquity, a leading New York City based independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued a 2Q15 update note on DelMar Pharmaceuticals, Inc. (OTCQX: DMPI), a biotechnology company focused on proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments.
DelMar Pharmaceuticals to Present at the 27th Annual ROTH Conference on March 10, 2015
PR Newswire - Tue Mar 03, 7:00AM CST
DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) (DelMar and the Company), a biopharmaceutical company focused on developing and commercializing proven cancer therapies in new orphan drug indications, today announced that it will be presenting at the 27th Annual ROTH Conference being held March 8-11, 2015, at The Ritz-Carlton, Laguna Niguel, in Dana Point, California.
DelMar Pharmaceuticals Receives Notice of Allowance of Fourth U.S. Patent Covering Methods of Use and Compositions for VAL-083
PR Newswire - Mon Mar 02, 10:17AM CST
DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) (DelMar and the Company), a company focused on developing and commercializing proven cancer therapies in new orphan drug indications, today announced that it received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for patent application number 13/817,096 entitled, "Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dianhydrogalactitol and diacetyldianhydrogalactitol."
DelMar Pharmaceuticals Announces December 31, 2014 Financial Results and Provides Corporate Update
PR Newswire - Thu Feb 12, 7:00AM CST
DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"
DelMar Pharmaceuticals names Lynda Cranston to board
M2 - Thu Feb 12, 6:41AM CST
Cancer therapies company DelMar Pharmaceuticals (OtherOTC
DelMar Pharmaceuticals Appoints Lynda Cranston, BScN, MScN, ICD.D, to the Board of Directors
PR Newswire - Wed Feb 11, 7:13AM CST
DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"
DelMar Pharmaceuticals Completes Offer to Exchange Common Stock for Outstanding Warrants
PR Newswire - Tue Feb 10, 8:35AM CST
DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"
DelMar Pharmaceuticals awarded notice of allowance for third US patent for VAL-083, expanding to three US patents and one international patent
M2 - Wed Jan 14, 6:54AM CST
Cancer therapies company DelMar Pharmaceuticals (Other OTC
DelMar Pharmaceuticals Receives Notice of Allowance for Third US Patent for VAL-083
PR Newswire - Tue Jan 13, 7:00AM CST
DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar", "the Company"
DelMar Pharmaceuticals Provides Update on VAL-083 Clinical Trial and Outlines Corporate Objectives for 2015
PR Newswire - Mon Jan 12, 7:00AM CST
DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar", "the Company) provided an update on the Company's ongoing Phase I/II clinical trial with VAL-083 as a potential new treatment for refractory glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer. In addition, DelMar outlined its corporate objectives for 2015.